Robert F. Werner Sells 1,448 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) CAO Robert F. Werner sold 1,448 shares of the company's stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $64,580.80. Following the completion of the transaction, the chief accounting officer now owns 45,620 shares of the company's stock, valued at $2,034,652. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Twist Bioscience Stock Down 0.3 %

Shares of NASDAQ TWST traded down $0.12 during mid-day trading on Friday, hitting $45.40. 638,602 shares of the company were exchanged, compared to its average volume of 941,083. The firm has a market cap of $2.66 billion, a price-to-earnings ratio of -11.88 and a beta of 1.78. The stock has a 50 day simple moving average of $43.69 and a 200-day simple moving average of $45.64. Twist Bioscience Co. has a 1-year low of $15.85 and a 1-year high of $60.90.

Institutional Trading of Twist Bioscience

Several hedge funds and other institutional investors have recently made changes to their positions in TWST. Intech Investment Management LLC purchased a new position in Twist Bioscience during the third quarter worth about $714,000. Jennison Associates LLC increased its position in Twist Bioscience by 29.6% during the 3rd quarter. Jennison Associates LLC now owns 377,894 shares of the company's stock worth $17,073,000 after purchasing an additional 86,399 shares during the period. Thrivent Financial for Lutherans acquired a new position in Twist Bioscience during the 3rd quarter worth approximately $43,992,000. Chesapeake Capital Corp IL raised its stake in shares of Twist Bioscience by 27.9% during the 3rd quarter. Chesapeake Capital Corp IL now owns 6,176 shares of the company's stock worth $287,000 after buying an additional 1,347 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its holdings in shares of Twist Bioscience by 7.7% in the 3rd quarter. Victory Capital Management Inc. now owns 331,809 shares of the company's stock valued at $14,991,000 after buying an additional 23,638 shares during the period.

Analysts Set New Price Targets

TWST has been the subject of a number of research analyst reports. Leerink Partners upped their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a research report on Thursday, October 17th. Robert W. Baird increased their price objective on Twist Bioscience from $40.00 to $46.00 and gave the company an "outperform" rating in a report on Monday, August 5th. Barclays lowered their target price on shares of Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, August 5th. JPMorgan Chase & Co. upped their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an "underweight" rating in a research report on Monday, August 5th. Finally, Evercore ISI increased their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 1st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $51.22.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.